These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26286818)

  • 1. The characteristics of a cohort who tamper with prescribed and diverted opioid medications.
    Larance B; Lintzeris N; Bruno R; Peacock A; Cama E; Ali R; Kihas I; Hordern A; White N; Degenhardt L
    J Subst Abuse Treat; 2015 Nov; 58():51-61. PubMed ID: 26286818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
    Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids.
    Peacock A; Bruno R; Cama E; Kihas I; Larance B; Lintzeris N; Hordern A; White N; Ali R; Degenhardt L
    Drug Alcohol Rev; 2015 Nov; 34(6):611-22. PubMed ID: 26084592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
    Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
    Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
    Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
    Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort.
    Campbell G; Nielsen S; Larance B; Bruno R; Mattick R; Hall W; Lintzeris N; Cohen M; Smith K; Degenhardt L
    Pain Med; 2015 Sep; 16(9):1745-58. PubMed ID: 26011277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.
    Peacock A; Degenhardt L; Hordern A; Larance B; Cama E; White N; Kihas I; Bruno R
    Int J Drug Policy; 2015 Dec; 26(12):1265-72. PubMed ID: 26123898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study.
    Degenhardt L; Bruno R; Lintzeris N; Hall W; Nielsen S; Larance B; Cohen M; Campbell G
    Lancet Psychiatry; 2015 Apr; 2(4):314-22. PubMed ID: 26360084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study.
    Peacock A; Bruno R; Larance B; Lintzeris N; Nielsen S; Ali R; Dobbins T; Degenhardt L
    Drug Alcohol Depend; 2016 Sep; 166():125-33. PubMed ID: 27430400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversion of prescribed opioids by people living with chronic pain: results from an Australian community sample.
    Belcher J; Nielsen S; Campbell G; Bruno R; Hoban B; Larance B; Lintzeris N; Degenhardt L
    Drug Alcohol Rev; 2014 Jan; 33(1):27-32. PubMed ID: 24251668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study.
    Campbell G; Hall WD; Peacock A; Lintzeris N; Bruno R; Larance B; Nielsen S; Cohen M; Chan G; Mattick RP; Blyth F; Shanahan M; Dobbins T; Farrell M; Degenhardt L
    Lancet Public Health; 2018 Jul; 3(7):e341-e350. PubMed ID: 29976328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis.
    Yarborough BJ; Stumbo SP; Janoff SL; Yarborough MT; McCarty D; Chilcoat HD; Coplan PM; Green CA
    Drug Alcohol Depend; 2016 Oct; 167():49-56. PubMed ID: 27520885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
    Sankey C; Setnik B; Harsanyi Z; Michalko K; Yang Z; Geoffroy P
    J Opioid Manag; 2016; 12(2):149-59. PubMed ID: 27194200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study.
    Nielsen S; Campbell G; Peacock A; Smith K; Bruno R; Hall W; Cohen M; Degenhardt L
    Aust Health Rev; 2016 Nov; 40(5):490-499. PubMed ID: 26599263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study.
    Campbell G; Mattick R; Bruno R; Larance B; Nielsen S; Cohen M; Lintzeris N; Shand F; Hall WD; Hoban B; Kehler C; Farrell M; Degenhardt L
    BMC Pharmacol Toxicol; 2014 Mar; 15():17. PubMed ID: 24646721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic pain.
    Setnik B; Roland CL; Pixton GC; Sommerville KW
    Postgrad Med; 2017 Jan; 129(1):5-11. PubMed ID: 27782769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.